Gyros AB, a leader in the automation of miniaturized immunoassays, announced today that it has signed agreements with Alpha Analytical PTE Ltd (Alpha), Spinco Biotech Pvt Ltd (Spinco) and HVD Vertriebs Ges.m.b.H (HVD) to become sole distributors of the company’s immunoassay platform for the biopharmaceutical industry in their respective markets.
Erik Walldén, CEO at Gyros, commented on the company’s selection: “Alpha is a well-established provider of analytical tools to the growing biopharmaceutical industry in Singapore. Both Spinco, a distributor with broad coverage of the Indian market, and HVD, well-known throughout the Middle East, Russia and Africa, have an excellent reputation for customer service. Such factors featured significantly in our choice.”
Mr Walldén continued: “Following a successful year in which we increased our presence significantly in North America and Europe and established distributorships in Japan and Korea, we believe the time is right to continue to expand our global coverage. We look forward to a fruitful relationship with our new partners.”
Major biopharmaceutical companies and their service providers currently utilize the Gyros immunoassay platform to boost time-critical workflows and meet increasing regulatory demands in the development of biotherapeutics and vaccines. By reducing turnaround times and enabling scientists to make data-driven decisions based on high quality data, the Gyros platform increases overall productivity and efficiency. Advantages such as unattended running of samples and assay development, within days rather than months, ensure substantial time-saving for analysts. Working at nanoliter scale cuts sample consumption and significantly reduces the cost of preclinical studies. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.